Martin H. Huber Jr. - Feb 22, 2022 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
PRESIDENT OF R&D AND CMO
Signature
/s/ Chris Frankenfield, Attorney-in-Fact
Stock symbol
XLO
Transactions as of
Feb 22, 2022
Transactions value $
$0
Form type
4
Date filed
2/24/2022, 04:30 PM
Previous filing
Feb 3, 2022
Next filing
Jun 10, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +65K $0.00 65K Feb 22, 2022 Common Stock 65K $12.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was granted on February 22, 2022 and shall vest on March 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until February 1, 2026.